Banque Pictet & Cie SA Has $2.58 Million Position in Repligen Corporation $RGEN

Key Points

• Banque Pictet & Cie SA has reduced its stake in Repligen Corporation by 15.6%, now holding 20,724 shares valued at approximately $2.58 million.
• Multiple institutional investors increased their holdings in Repligen, with Price T Rowe Associates raising their stake by 6.0%, and the stock is predominantly owned by institutional investors at 97.64%.
• Analysts have a consensus rating of "Moderate Buy" for Repligen shares, with target prices ranging from $150.00 to $205.00 following several upgrades from firms like Royal Bank of Canada and Evercore ISI.

Banque Pictet & Cie SA reduced its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 15.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,724 shares of the biotechnology company's stock after selling 3,820 shares during the period. Banque Pictet & Cie SA's holdings in Repligen were worth $2,578,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in Repligen by 6.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company's stock worth $962,711,000 after acquiring an additional 430,039 shares in the last quarter. Alliancebernstein L.P. raised its holdings in Repligen by 1.3% during the first quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company's stock worth $130,317,000 after acquiring an additional 13,284 shares in the last quarter. Conestoga Capital Advisors LLC raised its holdings in Repligen by 3.4% during the first quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock worth $124,727,000 after acquiring an additional 32,665 shares in the last quarter. New York State Common Retirement Fund raised its holdings in Repligen by 7.6% during the first quarter. New York State Common Retirement Fund now owns 625,388 shares of the biotechnology company's stock worth $79,574,000 after acquiring an additional 43,946 shares in the last quarter. Finally, Stephens Investment Management Group LLC raised its holdings in Repligen by 0.5% during the first quarter. Stephens Investment Management Group LLC now owns 539,542 shares of the biotechnology company's stock worth $68,651,000 after acquiring an additional 2,741 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on RGEN shares. Royal Bank Of Canada reiterated an "outperform" rating and set a $205.00 target price on shares of Repligen in a report on Tuesday, September 2nd. Wells Fargo & Company dropped their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a report on Wednesday, July 30th. Stephens upgraded Repligen to an "overweight" rating and set a $160.00 target price on the stock in a report on Tuesday, July 22nd. Barclays started coverage on Repligen in a report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 target price on the stock. Finally, Evercore ISI upgraded Repligen from an "in-line" rating to an "outperform" rating and upped their target price for the stock from $130.00 to $155.00 in a report on Monday. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $168.75.

Repligen Price Performance

NASDAQ:RGEN opened at $125.61 on Friday. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The stock's 50 day moving average price is $120.22 and its two-hundred day moving average price is $125.78. The firm has a market capitalization of $7.07 billion, a price-to-earnings ratio of -502.42, a P/E/G ratio of 2.24 and a beta of 1.07. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). The business had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. Repligen's quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Insider Buying and Selling at Repligen

In other news, Director Martin D. Madaus bought 1,800 shares of the stock in a transaction dated Friday, August 8th. The shares were bought at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the purchase, the director owned 1,800 shares in the company, valued at approximately $201,834. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.